Charles Gordon

Charles Gordon

Auto-generated profile, based on publicly available information

Charles Gordon

LivaNova PLC (or a Subsidiary) London UK

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2024 in Brain Stimulation
Verified
Journal Article
Open access
CCCharles R. Conway
Charles R. Conway
SAScott T. Aaronson
Scott T. Aaronson
HSHarold A. Sackeim
Harold A. Sackeim
MGMark S. George
Mark S. George
JZJohn Zajecka
John Zajecka
ARA. John Rush
A. John Rush
Few treatments are available for individuals with marked treatment-resistant depression (TRD). Evaluate the safety and effectiveness of FDA-approved adjunctive vagus nerve stimulation (VNS) in patients with marked TRD. This 12-month, multicenter, double-blind, sham-controlled trial included 493 adults with marked treatment-resistant major depression who were randomized to active or no-stimulation sham VNS for 12 months. The primary outcome was percent time in response across months 3-12, with response defined as a ≥50 % change from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS). Several secondary endpoints were evaluated. Overall, 88.4 % of participants completed the trial. Percent time in MADRS response did not distinguish active from sham VNS. However, ratings from on-site clinicians (Clinical Global Inventory-Impression [CGI-I]), patients (Quick Inventory of Depressive Symptomology-Self Report [QIDS-SR]), and offsite masked raters (Quick Inventory of Depressive Symptomology-Clinician [QIDS-C]) revealed antidepressant benefits significantly favoring active VNS. Active VNS demonstrated significantly more percent time in response on the CGI-I (P = 0.004) and QIDS-SR (P = 0.049), and significantly more percent time in partial response (PR; symptom improvement ≥30 %) on the CGI-I (P < 0.001) and QIDS-C (P = 0.006) versus sham VNS. Active VNS exceeded sham VNS in rate of dyspnea (P = 0.035), a known side effect of VNS. No new adverse events were identified. Percent time in MADRS response did not distinguish the treatment groups, but on multiple instruments time in response and PR showed a positive treatment effect. VNS was found safe and effective in participants with marked TRD.

10 September 2024 in Epilepsia Open
Verified
Journal Article
Open access
NTNaoki Tani
Naoki Tani
MDMaxine Dibué
Maxine Dibué
RVRyan Verner
Ryan Verner
SNStephany Mai Nishikawa
Stephany Mai Nishikawa
CGCharles Gordon
Charles Gordon
HKHaruhiko Kishima
Haruhiko Kishima
Objective: Amount of seizure‐free days is a critical determinant of quality of life (QoL) in patients with drug‐resistant epilepsy (DRE). The fractions of patients experiencing prolonged periods of seizure freedom with adjunctive vagus nerve stimulation (VNS) have yet to be assessed on a large scale.Methods: Retrospective analysis of patients in the Japanese VNS prospective observational registry who experienced at least 1 year of seizure freedom from all seizures, focal seizures, or tonic–clonic seizures (TCS), as well as patient‐reported change in QoL in these groups.Results: The study included 362 patients with DRE, 147 were female (40.6%), and the median age at VNS implant was 23.0 years (range: 1.0–73.0). A total of 225 patients reported focal seizures and 184 patients reported TCS. After 36 months of adjunctive VNS, the cumulative proportion of patients experiencing at least 1 year of complete seizure freedom was 11% (38/356) with an average duration of seizure freedom of 19.4 months. In patients with focal seizures, 25% (n = 57/225) experienced at least 1 year of freedom from focal seizures with an average duration of 24.8 months. Higher cumulative rates of freedom from TCS were observed: 55% (n = 101/184) experienced at least 1 year without TCS with an average duration of TCS‐free periods of 28.9 months. 82.1% of patients with 12‐month complete seizure freedom reported markedly improved or improved QoL compared with 51.9% of patients who were not seizure‐free. QoL changes in patients with 12‐month seizure freedom from TCS and focal seizures were similar: 61.8% and 63% of respective patients reported either markedly improved or improved QoL at 36 months.Significance: Complete seizure freedom is rare in patients treated with VNS; however, this analysis found approximately half of patients who experienced TCS prior to VNS experienced prolonged periods of freedom from TCS with adjunctive VNS.Plain Language Summary: We studied patients in Japan with epilepsy that is difficult to treat. To understand if adding vagus nerve stimulation (VNS) helps such patients, we looked at which patients stopped having all seizures or stopped having a specific seizure type (such as tonic–clonic seizures or focal seizures), and how long these periods lasted. With VNS treatment, about 2 out of 4 patients with tonic–clonic seizures and 1 out of 4 patients with focal seizures had more time without these seizure types. Without seizures, patients felt better about their daily lives. Even patients who still had seizures felt better about their daily lives after 3 years of VNS treatment.Trial Registration: The clinical trial registry number is UMIN000014728.

14 April 2025 in Journal of Mood & Anxiety Disorders
Verified
Journal Article
Open access
CCCharles R. Conway
Charles R. Conway
ARA. John Rush
A. John Rush
CGCharles Gordon
Charles Gordon
SPSheldon H. Preskorn
Sheldon H. Preskorn
HSHarold A. Sackeim
Harold A. Sackeim
MBMark T. Bunker
Mark T. Bunker
The treatment of depression aims to improve depressive symptoms, daily function and quality of life (QoL). These exploratory analyses of a database of convenience from the RECOVER trial evaluated how a “tripartite” metric based on these 3 outcome domains might perform in treatment-resistant depression (TRD). Outcome domains included depressive symptoms (MADRS, QIDS-C, QIDS-SR), function (WPAI item-6) and QoL (Mini-Q-LES-Q) obtained at months 3, 6, 9 and 12 in outpatients with markedly TRD in the double-blind RECOVER trial that compared sham to active adjunctive vagus nerve stimulation (VNS). For each domain, clinically meaningful differences were defined a priori. Analyses addressed 3 questions: 1) Does each domain detect meaningful benefits undetected by the other domains? 2) Is the tripartite metric validated by an independent clinician-rated global index of improvement (CGI-I)? 3) How well does the tripartite metric detect treatment group differences in the RECOVER trial? Clinically meaningful reductions in depressive symptoms alone missed 25–51 % of all participants who evidenced clinically meaningful benefits in depressive symptoms, function or QoL. The tripartite metric strongly correlated with CGI-I ratings (tetrachoric r = 0.73–0.85), with stronger relationships than each component individually. The tripartite metric successfully separated active from sham adjunctive VNS in a 1-year trial of patients with markedly TRD. Symptoms, function and QoL capture distinct, clinically significant and valid outcomes that identify persons with markedly TRD with a range of clinically meaningful benefits. Whether these results pertain to other major depressive disorder patient groups and treatments deserves study.

12 May 2026 in Epilepsia Open
Verified
Journal Article
Open access
KEKatherine Eggleston
Katherine Eggleston
JCJustine Curley
Justine Curley
RVRyan Verner
Ryan Verner
MDMaxine Dibue
Maxine Dibue
CGCharles Gordon
Charles Gordon
KNKathryn Nichol
Kathryn Nichol
Objective: Most therapies for drug‐resistant epilepsy (DRE) focus on focal‐onset seizures, the most common seizure types. Studying primary generalized tonic–clonic seizures (PGTCS) is more challenging due to diagnostic and recruitment difficulties. While vagus nerve stimulation (VNS) therapy is globally established in DRE with focal‐onset seizures, approved indications vary by region. This study assesses the safety and effectiveness of VNS therapy in individuals with drug‐resistant PGTCS. Methods: Data from five studies were included in the analysis. The PGTCS group included 170 participants with reported PGTCS who received VNS therapy and completed 24 months of follow‐up. Outcomes included observed and Bayesian‐estimated PGTCS responder rates (≥50% seizure reduction) and seizure frequency changes. Observed rates were determined from clinical studies, while Bayesian responder rates were estimated using a hierarchical model. Results: The Bayesian hierarchical model estimated the 24‐month PGTCS responder rate for patients in CORE‐VNS to be 65.2% (95% credible interval: 55.1%–75.1%). The Bayesian estimate at 24 months for responder rates across all studies was 65.5%. Most responders (91.7%) maintained their response from 6 and 12 months to 24 months. Median seizure frequency decreased by 71.4% for PGTCS and 62.5% for all seizures at 24 months. Treatment‐emergent adverse events (TEAEs) were low and consistent with those seen in people with focal‐onset seizures treated with VNS therapy. No new safety concerns were identified, including no increased risk of Status Epilepticus (SE) or death. Significance: These findings support VNS therapy as a safe and effective treatment for reducing PGTCS in participants with DRE. Plain Language Summary: Primary generalized tonic–clonic seizures (PGTCS) carry higher risks of complications and death than focal‐onset seizures. Vagus nerve stimulation (VNS therapy) is approved for drug‐resistant PGTCS outside the USA. Data from five LivaNova‐sponsored clinical studies show that VNS therapy is safe and effective in adults and children. Among 170 participants, about 66% had a ≥50% reduction in PGTCS at 24 months, and 92% of early responders maintained improvement. Among 149 participants, median PGTCS frequency fell by 71%. Treatment‐emergent adverse events were low, with no new safety concerns identified.

9 April 2002 in ChemInform
Verified
Journal Article
Closed access
PDF file
CGCharles M. Gordon
Charles M. Gordon